A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Neoplasms by site
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Apr 2012 New trial record